Cargando…

Synthesis of [(18)F]FMISO, a hypoxia-specific imaging probe for PET, an overview from a radiochemist’s perspective

BACKGROUND: [(18)F]fluoromisonidazole ([(18)F]FMISO, 1H-1-(3-[(18)F]fluoro-2-hydroxypropyl)-2-nitroimidazole) is a commonly used radiotracer for imaging hypoxic conditions in cells. Since hypoxia is prevalent in solid tumors, [(18)F]FMISO is in clinical application for decades to explore oxygen dema...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kniess, Torsten, Zessin, Jörg, Mäding, Peter, Kuchar, Manuela, Kiss, Oliver, Kopka, Klaus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006378/ https://www.ncbi.nlm.nih.gov/pubmed/36897480 http://dx.doi.org/10.1186/s41181-023-00190-7

Ejemplares similares

Biodistribution and radiation dosimetry of the novel hypoxia PET probe [(18)F]DiFA and comparison with [(18)F]FMISO
por: Watanabe, Shiro, et al.
Publicado: (2019)

First Comparison between [18f]-FMISO and [18f]-Faza for Preoperative Pet Imaging of Hypoxia in Lung Cancer
por: Thureau, Sébastien, et al.
Publicado: (2021)

Monitoring Tumor Hypoxia Using (18)F-FMISO PET and Pharmacokinetics Modeling after Photodynamic Therapy
por: Tong, Xiao, et al.
Publicado: (2016)

The role of necrosis, acute hypoxia and chronic hypoxia in (18)F-FMISO PET image contrast: a computational modelling study
por: Warren, Daniel R, et al.
Publicado: (2016)

A patient-specific computational model of hypoxia-modulated radiation resistance in glioblastoma using (18)F-FMISO-PET
por: Rockne, Russell C., et al.
Publicado: (2015)

Assessment of tumor hypoxia and perfusion in recurrent glioblastoma following bevacizumab failure using MRI and (18)F-FMISO PET
por: Huang, Shiliang, et al.
Publicado: (2021)

Kinetic Evaluation of the Hypoxia Radiotracers [(18)F]FMISO and [(18)F]FAZA in Dogs with Spontaneous Tumors Using Dynamic PET/CT Imaging
por: Choen, Sangkyung, et al.
Publicado: (2022)

(18)F-FMISO-PET Hypoxia Monitoring for Head-and-Neck Cancer Patients: Radiomics Analyses Predict the Outcome of Chemo-Radiotherapy
por: Carles, Montserrat, et al.
Publicado: (2021)

Elimination of tumor hypoxia by eribulin demonstrated by (18)F-FMISO hypoxia imaging in human tumor xenograft models
por: Zhao, Songji, et al.
Publicado: (2019)

Usefulness of FMISO—PET for Glioma Analysis
por: Kobayashi, Hiroyuki, et al.
Publicado: (2013)

Increased [(18)F]FMISO accumulation under hypoxia by multidrug-resistant protein 1 inhibitors
por: Shimizu, Yoichi, et al.
Publicado: (2021)

Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients
por: Bandurska-Luque, Anna, et al.
Publicado: (2019)

[(18)F]FMISO PET/CT as a preoperative prognostic factor in patients with pancreatic cancer
por: Yamane, Tomohiko, et al.
Publicado: (2019)

Targeting Hypoxia Using Evofosfamide and Companion Hypoxia Imaging of FMISO-PET in Advanced Biliary Tract Cancer
por: Yoon, Jeesun, et al.
Publicado: (2021)

Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET
por: Wiedenmann, Nicole, et al.
Publicado: (2018)

Simultaneous Mapping of Vasculature, Hypoxia, and Proliferation Using Dynamic Susceptibility Contrast MRI, (18)F-FMISO PET, and (18)F-FLT PET in Relation to Contrast Enhancement in Newly Diagnosed Glioblastoma
por: Collet, Solène, et al.
Publicado: (2021)

Voxel based comparison and texture analysis of (18)F-FDG and (18)F-FMISO PET of patients with head-and-neck cancer
por: Kroenke, Markus, et al.
Publicado: (2019)

Noninvasive evaluation of (18)F-FDG/(18)F-FMISO-based Micro PET in monitoring hepatic metastasis of colorectal cancer
por: Zhang, Mingyu, et al.
Publicado: (2018)

Evaluation of Fluorine-18-Labeled α1(I)-N-Telopeptide Analogs as Substrate-Based Radiotracers for PET Imaging of Melanoma-Associated Lysyl Oxidase
por: Kuchar, Manuela, et al.
Publicado: (2018)

Correction to: Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET
por: Wiedenmann, Nicole, et al.
Publicado: (2018)

Radiopharmacologist’s and Radiochemist’s View on Targeting the Eph/Ephrin Receptor Tyrosine Kinase System
por: Neuber, Christin, et al.
Publicado: (2020)

Hypoxia Imaging Using PET and SPECT: The Effects of Anesthetic and Carrier Gas on [(64)Cu]-ATSM, [(99m)Tc]-HL91 and [(18)F]-FMISO Tumor Hypoxia Accumulation
por: Kersemans, Veerle, et al.
Publicado: (2011)

[(18)F]FMISO PET/CT imaging of hypoxia as a non-invasive biomarker of disease progression and therapy efficacy in a preclinical model of pulmonary fibrosis: comparison with the [(18)F]FDG PET/CT approach
por: Tanguy, Julie, et al.
Publicado: (2021)

Evaluation of (18)F-FMISO PET and (18)F-FDG PET Scans in Assessing the Therapeutic Response of Patients With Metastatic Colorectal Cancer Treated With Anti-Angiogenic Therapy
por: Lee, Sze Ting, et al.
Publicado: (2021)

Comparison of (18)F-FES, (18)F-FDG, and (18)F-FMISO PET Imaging Probes for Early Prediction and Monitoring of Response to Endocrine Therapy in a Mouse Xenograft Model of ER-Positive Breast Cancer
por: He, SiMin, et al.
Publicado: (2016)

(18)F-FMISO PET Imaging Identifies Hypoxia and Immunosuppressive Tumor Microenvironments and Guides Targeted Evofosfamide Therapy in Tumors Refractory to PD-1 and CTLA-4 Inhibition
por: Reeves, Kirsten M., et al.
Publicado: (2022)

The accumulation mechanism of the hypoxia imaging probe “FMISO” by imaging mass spectrometry: possible involvement of low-molecular metabolites
por: Masaki, Yukiko, et al.
Publicado: (2015)

Repurposing (18)F-FMISO as a PET tracer for translational imaging of nitroreductase-based gene directed enzyme prodrug therapy
por: Ruiz de Garibay, Gorka, et al.
Publicado: (2021)

Sequential [(18)F]FDG-[(18)F]FMISO PET and Multiparametric MRI at 3T for Insights into Breast Cancer Heterogeneity and Correlation with Patient Outcomes: First Clinical Experience
por: Andrzejewski, Piotr, et al.
Publicado: (2019)

Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma
por: Thézé, Benoît, et al.
Publicado: (2015)

FDG and FMISO PET-guided dose escalation with intensity-modulated radiotherapy in lung cancer
por: Thureau, Sébastien, et al.
Publicado: (2018)

ANGI-1 ASSESSING THE THERAPEUTIC EFFECT OF BEVACIZUMAB USING FMISO-PET IN GBM THERAPY
por: Suzuki, Tomoya, et al.
Publicado: (2022)

Deuteration versus ethylation – strategies to improve the metabolic fate of an (18)F-labeled celecoxib derivative
por: Laube, Markus, et al.
Publicado: (2020)

FMISO-PET-derived brain oxygen tension maps: application to glioblastoma and less aggressive gliomas
por: Chakhoyan, Ararat, et al.
Publicado: (2017)

Quantitative MRI to Characterize Hypoxic Tumors in Comparison to FMISO PET/CT for Radiotherapy in Oropharynx Cancers
por: Gouel, Pierrick, et al.
Publicado: (2023)

Combination of FDG-PET and FMISO-PET as a treatment strategy for patients undergoing early-stage NSCLC stereotactic radiotherapy
por: Watanabe, Shiro, et al.
Publicado: (2019)

Assessment of the Prognostic Value of Radiomic Features in (18)F-FMISO PET Imaging of Hypoxia in Postsurgery Brain Cancer Patients: Secondary Analysis of Imaging Data from a Single-Center Study and the Multicenter ACRIN 6684 Trial
por: Muzi, Mark, et al.
Publicado: (2020)

PET probes beyond (18)F-FDG
por: Jiang, Lei, et al.
Publicado: (2014)

Automated radiosynthesis of two (18)F-labeled tracers containing 3-fluoro-2-hydroxypropyl moiety, [(18)F]FMISO and [(18)F]PM-PBB3, via [(18)F]epifluorohydrin
por: Ohkubo, Takayuki, et al.
Publicado: (2021)

Comparison of DCE‐MRI kinetic parameters and FMISO‐PET uptake parameters in head and neck cancer patients
por: Simoncic, Urban, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bq9u7d18sbuqolnvukjvqv56a1